** Brokerage Wells Fargo initiates coverage on medtech firm LeMaitre Vascular LMAT.O with an "equal weight" rating and a PT of $95
** Brokerage says LMAT could be poised for growth in 2025 if it pursues strategic mergers and acquisitions; adds that the company has $300 million available for deals that could bolster its device portfolio
** Wells Fargo observes LMAT may acquire companies that make surgical sealants, devices that block blood flow and clips for tying off blood vessels
** "We believe that the stock fully prices in an optimistic outlook for pricing and volume growth in 2025 and beyond" - brokerage
** Stock up about 55% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.